Stock Price Quote

SOLARA ACTIVE PHARMA SCIENCES LTD.

NSE : SOLARABSE : 541540ISIN CODE : INE624Z01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE551.654.45 (+0.81 %)
PREV CLOSE ( ) 547.20
OPEN PRICE ( ) 550.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 42434
TODAY'S LOW / HIGH ( )526.60 567.00
52 WK LOW / HIGH ( )287 606.95
NSE551.604 (+0.73 %)
PREV CLOSE( ) 547.60
OPEN PRICE ( ) 547.60
BID PRICE (QTY) 551.60 (284)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 644905
TODAY'S LOW / HIGH( ) 526.35 568.00
52 WK LOW / HIGH ( )286 606.4
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 23-02 2017
Management Info
- Chairman Poorvank Purohit - Managing Director
Registered Office

Address 201, Devavrata,Sector 17,Vashi,
Navi Mumbai,
Maharashtra-400703

Phone 022 2789 2924 / 2789 3199

Email investors@solara.co.in

Website www.solara.co.in

Registrars Details
Cameo Corporate Services Ltd
Subramanian Buildings No 1 ,Club House Road,,Chennai
Listing : BSE, NSE

NEWS

22Apr Clarification sought from Solara Acti
The Exchange has sought clarification from Solara Active Pharma Sciences..
26Mar Solara Active Pharma Sciences gets nod
Solara Active Pharma Sciences has received approval from board of direct..
08Mar Solara Active Pharma Sciences informs
Pursuant to Section 110 of the Companies Act, 2013 read with the Compani..
08Mar Solara Active Pharma Sciences informs
Solara Active Pharma Sciences has informed that the Board in its meeting..
21Feb Solara Active Pharma Sciences informs
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-2753.3-222.099999999999
Gross Profit -2753.3 -447.799999999999
Operating Profit -1612.31561.8
Net Sales 2487.314438.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2621.00 (5.75%)
M.Cap ( in Cr)1619.26
Glaxosmithkline Phar (BSE)
peergroup  2079.80 (7.06%)
M.Cap ( in Cr)35233.07
TTK Healthcare (BSE)
peergroup  1591.35 (5.77%)
M.Cap ( in Cr)2248.63
Cipla (BSE)
peergroup  1398.80 (3.79%)
M.Cap ( in Cr)112938.41
Torrent Pharma (BSE)
peergroup  2685.00 (1.85%)
M.Cap ( in Cr)90872.60

Shareholding Pattern

NON-INSTITUTION 50.74%
PROMOTERS 30.49%
MUTUAL FUNDS/UTI 1.71%
FI/BANKS/INSURANCE 0.04%
GOVERNMENT 0%
FII 0%

About Solara Active Pharma Sciences Ltd.

Solara Active Pharma Sciences Ltd. was incorporated in the year 2017. Its today's share price is 551.65. Its current market capitalisation stands at Rs 1985.73 Cr. In the latest quarter, company has reported Gross Sales of Rs. 14438.1 Cr and Total Income of Rs.14659.5 Cr. The company's management includes Mohan Muthunarayanan, Rajiv Vijay Nabar, Rajendra Kumar Srivastava, Poorvank Purohit, S Murali Krishna, Ankur Nand Thadani, R Ramakrishnan, Kausalya Santhanam, Kartheek Chintalapati Raju, Arun Kumar.

It is listed on the BSE with a BSE Code of 541540 , NSE with an NSE Symbol of SOLARA and ISIN of INE624Z01016. It's Registered office is at 201, Devavrata,Sector 17,VashiNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.